Oncopeptides Initiates Real-World Study of Pepaxti in Spain

An announcement from Oncopeptides AB ( (SE:ONCO) ) is now available.

Oncopeptides AB has launched a new real-world evidence study in Spain to evaluate the use of its drug Pepaxti in routine clinical settings for patients with relapsed, refractory multiple myeloma. This study, named LAGOON, marks the first of its kind for Pepaxti in Spain and aims to collect data on the drug’s effectiveness and safety, supporting clinical decision-making and market development. The study’s findings will contribute to Oncopeptides’ efforts to provide relevant data to healthcare providers, payers, and regulators across Europe.

More about Oncopeptides AB

Oncopeptides is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company utilizes its proprietary Peptide Drug Conjugate platform to develop compounds that deliver cytotoxic agents into cancer cells. Oncopeptides’ flagship drug is being commercialized in Europe, with partnerships in South Korea, the Middle East, and Africa. The company, founded in 2000, operates in several European countries and is listed on Nasdaq Stockholm.

Average Trading Volume: 906,383

Current Market Cap: SEK422.1M

See more data about ONCO stock on TipRanks’ Stock Analysis page.